Critical reviews in oncology/hematologyReview
07 Jul 2025
Lung cancer remains a leading cause of cancer-related deaths globally, presenting significant clinical challenges despite advancements in therapeutic strategies.
Recent developments have highlighted the potential of lung cancer organoids as a promising tool to bridge basic science, drug development, and clinical therapeutics.
This review focuses on the innovative role of lung cancer organoids in translational research, particularly their ability to integrate and accelerate the development of personalized treatment strategies.
By mimicking patient-specific tumor microenvironments, lung cancer organoids provide an unparalleled platform for drug screening, evaluation of immune therapies, and assessment of anti-angiogenesis treatments.
We posit that lung cancer organoids represent a cutting-edge, multidisciplinary tool with the potential to revolutionize cancer treatment and improve patient outcomes through enhanced translational research.
Declaration of Competing Interest The authors declare that there are no conflicts of interest regarding the publication of this paper. All authors have contributed to the research and preparation of the manuscript, and they have no personal relationships or financial connections that could influence the work presented. All authors have reviewed the final manuscript and agree with its submission.
Article info
Journal issue:
Doi:
10.1016/j.critrevonc.2025.104840
Share: